儿童期免疫接种11年后青少年单剂4CMenB疫苗加强免疫的免疫原性
这项单中心上市后试验招募了2006年起在婴儿/学龄前阶段接种过3-5剂4CMenB的11岁以上儿童,按末剂接种年龄分为婴儿组和婴儿+学龄前组,并与年龄匹配的未接种对照(随机接受1剂或2剂)比较。结果显示,既往接种者单剂加强后1个月应答高于未接种对照;第180天时婴儿+学龄前组对5/99株的应答最高,而末剂在12月龄时单剂加强应答不够强。研究为描述性研究。
要点
- 既往接种4CMenB的青少年单剂加强后1个月应答高于未接种对照。
- 第180天婴儿+学龄前组对5/99株GMT为316.1(CI 158.4至630.8),高于未接种两剂组的84.5(CI 57.7至123.6)。
- 末剂在12月龄时青少年单剂加强应答不够强,对5/99株GMT为61.1(CI 14.8至252.4)。
核心结论
- 这项描述性研究提示,青少年期单剂接种后最高的SBA应答见于接受过学龄前剂次的参与者,提示12月龄以下B细胞记忆应答未被充分致敏。
研究设计与样本
- 单中心上市后试验,招募2006年起在婴儿/学龄前阶段接种过3-5剂4CMenB的11岁以上儿童。
- 分为末剂在12月龄接种的婴儿组和末剂在3岁接种的婴儿+学龄前组。
- 年龄匹配的未接种对照随机接受1剂(青少年1组)或第0天和第28天2剂(青少年2组)4CMenB。
- 使用人补体的血清杀菌抗体(SBA)试验针对三株参考菌株,在接种前及1、6、12个月检测。
主要发现
- 与未接种年龄匹配对照的单剂相比,既往接种与11岁时单剂加强后1个月更高的应答相关。
- 第180天,婴儿+学龄前组对5/99株的应答最高,GMT为316.1(CI 158.4至630.8),未接种青少年接受两剂的GMT为84.5(CI 57.7至123.6)。
- 末剂在12月龄接种时,青少年单剂应答不够强,对5/99株GMT为61.1(CI 14.8至252.4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical development of the meningococcal vaccine, 4CMenB, included 2 doses in vaccine-naïve adolescents, which was considered unlikely to be cost-effective for implementation. Theoretically, priming with 4CMenB in early childhood might drive strong immune responses after only a single booster dose in adolescents and reduce programmatic costs. To address this question, children over 11 years old who took part in previous trials involving the administration of 3-5 doses of 4CMenB at infant/preschool age from 2006 were recruited into a post licensure single-centre trial, and were divided into two groups: those who received their last dose at 12 months old (infant group) and those who received their last dose at 3 years old (infant + preschool group). Naïve age-matched controls were randomised to receive one (adolescent 1 group) or two doses at days 0 and 28 (adolescent 2 group) of 4CMenB. Serum bactericidal antibody (SBA) assays using human complement were performed against three reference strains prior to vaccination, and at 1, 6 and 12 months. Previous vaccination was associated with a higher response to a single booster dose at 11 years of age, one-month post-vaccination, when compared with a single dose in naïve age-matched controls. At day 180, the highest responses were observed in participants in the infant + preschool group against strain 5/99 (GMT 316.1 [CI 158.4 to 630.8]), as compared with naïve adolescents who received two doses (GMTs 84.5 [CI 57.7 to 123.6]). When the last dose was received at 12-months of age, responses to a single adolescent dose were not as robust (GMT 61.1 [CI 14.8 to 252.4] to strain 5/99). This descriptive study indicates that the highest SBA responses after a single dose in adolescence were observed in participants who received a preschool dose, suggesting that B cell memory responses are not sufficiently primed at less than 12 months of age. Trial registration EudraCT 2017-004732-11, ISRCTN16774163.
引用
- Rollier CS, Dold C, Blackwell L, et al. Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation. Vaccine. 2022. PMID: 35697571. doi:10.1016/j.vaccine.2022.04.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。